DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20175493

Association of recurrent pregnancy loss and anticardiolipin antibodies: prevalence and prognosis of subsequent pregnancy in women with recurrent pregnancy loss

Malathi Verabelly, Swapnarani Seedipally

Abstract


Background: Anticardiolipin antibodies (ACA) are found with increased prevalence in women with unexplained recurrent pregnancy loss but their impact on future pregnancy is not clearly known. Therefore, present study objective was to compare the prevalence of ACA in patients with recurrent pregnancy loss and normal healthy pregnant women.

Methods: This prospective observational study from 100 pregnant women attending the outpatient department of Obstetrics and Gynaecology were studied. Study included 50 pregnant women with a history of three or more consecutive unexplained pregnancy loss as a study group and 50 pregnant women with two or more live children with no history of any previous pregnancy loss as a control group. Exclusion criteria included cases with any uterine anomaly, uterine structural abnormalities, induced abortions, infections, systemic disease, Rh-ve pregnancy, coagulation disorders and personal or family history of thrombosis.

Results: Overall, 9 patients tested positive for ACA, of which one (2%) patient was from the control group and remaining 8 (16%) were from study group. Overall, 42 (84%) patients had negative test for ACA in the study group and 49 (98%) patients in the control group. The live birth rate among study group was only 34 (68%) whereas all 50 (100%) pregnant women in the control group.

Conclusions: The findings described here in demonstrate that, ACA -positive patients are also the primary predictor of adverse pregnancy outcome and obstetric complications. Therefore, the role of early detection of ACA in all pregnant women is very important to prevent foetal outcomes and obstetric complications.

 


Keywords


Anticardiolipin antibodies, Pre-eclampsia, Pregnancy, IUGR

Full Text:

PDF

References


Stirrat GM. Recurrent miscarriage I: definition and epidemiology. Lancet. 1990;336(8716):673-5.

Berry CW, Bramabati B, Eskes TKAB, Exalto N, Fox H, Geraedts JPM et al. The Euro- Team Early Pregnancy (ETEP) protocol for recurrent miscarriage. Hum Reprod. 1995;10:1516-20.

Bricker L, Farquharson RG. Types of pregnancy loss in recurrent miscarriage: implications for research and clinical practice. Hum Reprod. 2002;17:1345-50.

Kutteh WH, Ermel LD. A clinical trial for the treatment of antiphospholipid antibody associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol. 1996 Apr;35(4):402-7.

Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gynecol. 1993 Jan;168(1 Pt 1):206-10.

Pattison N, Birdsall M, Chamley L, Lubbe W. Recurrent Foetal loss and the antiphospholipid syndrome, In: Recent Advances in Obstetrics and Gynecology, vol. 18, Ed. John Bonnar, Churchill Livingstone, London;1994

Lynch A, Marlar R, Murphy J, Davila G, Santos M, Rutledge J, Emlen W. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Intern Med. 1994;120:470-5.

Wilson WA1, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999 Jul;42(7):1309-11.

Ginsberg JS, Brill-Edwards P, Johnston M, Denburg JA, Andrew M, Burrows RF et al. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study. Blood. 1992;80:975-80.

Out HJ, Bruinse HW, Christianens GCML, Vliet MV, Groot PG, Nieuwenhuis HK et al. A prospective controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol. 1992;167:26-32.

Lockwood CJ, Romero R, Feinberg RF, Clyne LP, Coster B and Hobbins JC. The prevalence and biological significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol. 1989;160,439-443.

Infante-Rivard C, David M, Gauthier R, Rivard GE. Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. A case-control study. N Engl J Med. 1991 Oct 10;325(15):1063-6.

Pattison NS, Chamley LW, McKay EJ, Liggins GC, Butler WS. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynaecol. 1993 Oct 1;100(10):909-13.

Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective study of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol. 1995;86:555-9.

Barbui T, Cortelazzo S, Galli M, Parazzini F, Radici E, Rossi E, Finazzi G. Antiphospholipid antibodies in early repeated abortions: A case-controlled study. Fertil Steril. 1988;50:589-92.

Parazzini F, Acaia B, Faden D, Lovotti M, Marelli G, Cortelazzo S. Antiphospholipid antibodies and recurrent abortion. Obstet Gynecol. 1991;77:854-8.

Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod. 1995b;10:3301-4.

Harris EN, Gharavi AE, Hughes GRV. Anti-cardiolipin antibody testing: The need for standardization. Arthritis Rheum. 1987b;30:835-7.

Peaceman AM, Silver RK, MacGregor SN, Socol ML. Interlaboratory variation in antiphospholipid antibody testing. Am J Obstet Gynecol. 1992 Jun 1;166(6):1780-7.

Roberts JM, Macara LM, Chalmers EA, Smith GCS. Inter-assay variation in antiphospholipid antibody testing. Br J Obstet Gynaecol. 2002;109:348-9.

Rai RS, Regan L, Clifford K, Pickering W, Dave M, Mackie L et al. Antiphospholipid antibodies and b2-g1ycoprotein I in 500 women with recurrent miscarriage: Results of a comprehensive screening approach. Hum Reprod. 1995a;10:2001-5.

Donohoe S, Quenby S, Mackie I, Panal G, Farquharson R, Malia R et al. Fluctuations in levels of antiphospholipid antibodies and increased coagulation activation markers in normal and heparin-treated antiphospholipid syndrome pregnancies. Lupus. 2002;11:11-20.

Quenby SM, Farquharson RG. Predicting recurring miscarriage: what is important? Obstet Gynecol. 1993;82:132-8.

Tulppala M, Palo ST, Ramsay T, Miettinen A, Salonen R, Ylikorkala O. A prospective study of 63 couples with a history of recurrent spontaneous abortion: contributing factors and outcome of subsequent pregnancies. Hum Reprod. 1993;8:764-770.

Kumar KS, Jyothy A, Prakash MS, Rani HS, Reddy PP. Beta 2-glycoprotein I dependent anticardiolipin antibodies and lupus anticoagulant in patients with recurrent pregnancy loss. J Postgrad Med. 2002 Jan-Mar;48(1):5-10.

Allen JY, Tapia-Santiago C, Kutteh WH. Antiphospholipid antibodies in patients with preeclampsia. Am J Reprod Immunol. 1996 Aug;36(2):81-5.

Moodley J, Bhoola V, Duursma J, Pudifin D, Byrne S, Kenoyer DG. The association of antiphospholipid antibodies with severe early-onset pre-eclampsia. S Afr Med J. 1995;85(2):105-7.

Branch DW, Andres R, Digre KB, Rote NS, Scott JR. The association of antiphospholipid antibodies with severe preeclampsia. Obstet Gynecol. 1989;73(4):541-5.